Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1138888

registered interest
date	15/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sickle Cell Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 May 2019 to Question 256313 on Sickle Cell Diseases, which services (a) NHS England, (b) clinical commissioning groups and (c) other public bodies commission for people with sickle cell disease; and what the per capita annual cost is of providing each of those services.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	277137
answer	answer is ministerial correction date of answer 19/07/2019 answer text <p>NHS England commissions specialised services for people living with sickle cell disease. These services are part of the specialised haemoglobinopathy services commissioned by NHS England across the country. NHS England spends over £60 million on sickle cell disease within these services annually - £60.4 million in 2017/18. Information about the services provided by individual clinical commissioning groups or other public bodies is not collected or held centrally.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/07/2019 09:46:21 answering member 4455 label Biography information for Seema Kennedy previous answer version 129855 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
tabling member	1533 label Biography information for Dame Diana Johnson

1138889

registered interest
date	15/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sickle Cell Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 May 2019 to Question 256313, which services (a) NHS England, (b) clinical commissioning groups and (c) other public bodies commission for sickle cell disease patients with (i) stroke, (ii) chronic kidney disease, (iii) end-stage renal disease and (iv) pulmonary hypertension; and what the annual per capita cost is of providing each of those services.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	277138
answer	answer is ministerial correction date of answer 19/07/2019 answer text <p>NHS England does not commission separate services for sickle cell patients with stroke, chronic kidney disease, end-stage renal disease or pulmonary hypertension and so cannot provide annual per capita costs. These services are commissioned on behalf of all patients that require them, which would include people living with sickle cell disease.</p><p>NHS England has recently undertaken a review of haemoglobinopathy services to ensure that patients living with conditions such as sickle cell disease are able to access the high-quality services they need for their condition across the country. NHS England is now commissioning a networked-based model of care for specialised haemoglobinopathy services which will included specialist haemoglobinopathy teams across the country, regional haemoglobinopathy coordination centres and a National Haemoglobinopathy Panel. The new model will enable advice to be provided to local clinicians on the management of patients with sickle cell disease 24 hours a day, seven days a week. Haemoglobinopathy coordination centres will organise and run networks for sickle cell disease, providing leadership and education for local services.</p><p><strong> </strong></p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 19/07/2019 09:45:39 answering member 4455 label Biography information for Seema Kennedy
tabling member	1533 label Biography information for Dame Diana Johnson

1128812

registered interest
date	03/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sickle Cell Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of potential levels of inequality in (a) the life expectancy and (b) NHS service provision for patients with sickle cell disease compared to other NHS patients.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	259466
answer	answer is ministerial correction date of answer 06/06/2019 answer text <p>Evidence suggests that life expectancy for people with sickle cell disease is improving. This is due to a number of factors including:</p><p>- Improved newborn screening coverage to enable earlier diagnosis;</p><p>- Use of the National Haemoglobinopathy Registry to monitor individuals’ health, treatment and their annual reviews;</p><p>- Access to specific diagnostics and medication, such as hydroxyurea; and</p><p>- A Commissioning for Quality and Innovation (CQUIN) incentive has been in place for the last two years to improve access to apheresis for individuals with sickle cell disease.</p><p>All these factors are reflected in the service specification quality indicators which providers are required to report against so that implementation can be monitored.</p><p>It is anticipated that NHS England’s new model for specialised haemoglobinopathy services will be in place by early 2020. The new model is designed to improve access to specialist advice and care for patients, irrespective of where they live. The equality impact assessment on the new service model indicates that it will advance the promotion of equality and support the further reduction of health inequalities. This will be through ensuring that patients with thalassemia and sickle cell conditions have equitable access to high quality specialist care and support within specialised commissioned centres irrespective of where in the country they live. These centres will promote best practice in service delivery.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 06/06/2019 13:13:01 answering member 4455 label Biography information for Seema Kennedy
tabling member	1533 label Biography information for Dame Diana Johnson